Compostable Primary Packaging for Prescription Medicines
RedCarbonPharm is developing a regulated, compostable alternative to conventional blister packaging, designed to meet pharmaceutical stability, manufacturing, and compliance requirements while addressing the industry’s growing sustainability challenge.
The Scale of the Packaging Challenge
The challenge of pharmaceutical blister packaging is defined by scale, structural recyclability limitations, and accelerating regulatory pressure.
The global pharmaceutical industry generates approximately 300 million tonnes of plastic waste annually, making packaging reform a material industry-wide issue rather than a regional sustainability concern.
Around 50% of pharmaceutical plastic waste is single-use, driven by blister packaging formats that combine plastic and aluminium, preventing effective recycling and excluding composting as a viable end-of-life option.
In Europe alone, more than 1 billion non-recyclable blister packs are generated each year from statins, illustrating how this structural materials challenge manifests at scale even within a single therapeutic class.
Our Solution
RedCarbonPharm is developing a compostable primary packaging solution for solid oral dosage forms, designed from the outset to meet the functional, regulatory, and manufacturing requirements of prescription medicines.
Compostable Packaging
Compostable packaging intended to replace conventional blister formats for solid oral dosage forms.
Pharmaceutical Stability Requirements
Designed to provide appropriate barrier performance for pharmaceutical stability requirements.
Patent Protected
Patent-protected technology with a licensing-led commercial model.
Compatible
Compatible with existing pharmaceutical manufacturing and packaging workflows.
Why This Matters to Pharmaceutical Companies
-
Enables credible progress on sustainability objectives without compromising regulatory compliance or product integrity
-
Aligns with growing ESG, net-zero, and health-system procurement expectations
-
Provides a meaningful non-clinical differentiation opportunity in increasingly competitive therapeutic areas
-
Designed for scalable adoption across global pharmaceutical portfolios and markets